Abstract
Cytokine signaling generally occurs through receptors lacking tyrosine kinase activity. Aggregation of receptors leads to activation of receptor associated Janus kinases (Jaks) which in turn phosphorylate members of a family of transcription factors (STATs) that translocate to the nucleus and regulate gene expression. In the case of Interleukin-6 (IL-6), the consensus for signaling in B lineage cells has been that Jak1, Jak2 and Tyk2 are all phosphorylated upon ligand binding and participate in activation of downstream elements, in particular STAT3. In other cell types, Jak1 has been demonstrated to be absolutely required for IL-6 mediated activation of STAT3. In the present studies, we have identified a series of end stage B cell (plasma cell) lines that fail to express Jak1, but phosphorylate STAT3 in response to IL-6. No evidence was found for a requirement of other Jak family members in the activation of STAT3. STAT3 tyrosine phosphorylation was inhibited in a dose dependent manner by the MEK inhibitor U0126, but not by inhibitors of PI-3K or Src kinases. Moreover, STAT3 phosphorylation was similarly inhibited in lines expressing Jak1 wherein Jak1 was phosphorylated upon IL-6 stimulation and Jak1 phosphorylation was not inhibited by U0126. These results indicate that the MAPK pathway plays a critical role in IL-6 mediated tyrosine phosphorylation of STAT3 and suggests that Jak kinases may not be required in this cascade. Thus, it may be important to re-evaluate the role of Jak kinases in other cytokine signaling pathways as well.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR . 1995 J. Biol. Chem. 270: 27489–27494
Berger LC, Hawley TS, Lust JA, Goldman SJ, Hawley RG . 1994 Biochem. Biophys. Res. Commun. 202: 596–605
Bromberg J, Darnell JE . 2000 Oncogene 19: 2468–2473
Chung J, Uchida E, Grammer TC, Blenis J . 1997 Mol. Cell Biol. 17: 6508–6516
Daeipour M, Kumar G, Amaral MC, Nel AE . 1993 J. Immunol. 150: 4743–4753
De Vos J, Jourdan M, Tarte K, Jasmin C, Klein B . 2000 Br. J. Haematol. 109: 823–828
Eilers A, Georgellis D, Klose B, Schindler C, Ziemiecki A, Harpur AG, Wilks AF, Decker T . 1995 Mol. Cell. Biol. 15: 3579–3586
Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, Van Dyk DE, Pitts WJ, Earl RA, Hobbs F, Copeland RA, Magolda RL, Scherle PA, Trzaskos JM . 1998 J. Biol. Chem. 273: 18623–18632
Gadina M, Hilton D, Johnston J, Morinobu A, Lighvani A, Zhou Y-J, Visconti R, O'Shea JJ . 2001 Curr. Opin. Immunol. 13: 363–373
Guschin D, Rogers N, Briscoe J, Witthuhn B, Watling D, Horn F, Pellegrini S, Yasukawa K, Heinrich P, Stark GR, Ihle JN, Kerr IM . 1995 EMBO J. 14: 1421–1429
Hallek M, Neumann C, Schaffer M, Danhauser-Riedl S, von Bubnoff N, de Vos G, Druker BJ, Yasukawa K, Griffin JD, Emmerich B . 1997 Exp. Hematol. 25: 1367–1377
Hanke J, Gardner JP, Dow RL, Changelian PS, Brissete WH, Weringer EJ, Pollok BA, Connelly PA . 1996 J. Biol. Chem. 271: 695–701
Hilbert DM, Kopf M, Mock BA, Kohler G, Rudikoff S . 1995 J. Exp. Med. 182: 243–248
Hirano T, Ishihara K, Hibi M . 2000 Oncogene 19: 2548–2556
Hirano T . 1998 Int. Rev. Immunol. 16: 249–284
Ihle JN . 1995 Nature 377: 591–594
Karaghiosoff M, Neubauer H, Lassing C, Kovarik P, Schindler H, Pircher H, McCoy B, Bogdan C, Decker T, Brem G, Pfeffer K, Muller M . 2000 Immunity 13: 549–560
Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M, Kishimoto T, Zinkernagel R, Bluethmann H, Kohler G . 1994 Nature 368: 339–342
Krishnan K, Pine R, Krolewski JJ . 1997 Eur. J. Biochem. 247: 298–305
Kumar G, Gupta S, Wang S, Nel AE . 1994 J. Immunol. 153: 4436–4447
Leonard WJ, O'Shea JJ . 1998 Annu. Rev. Immunol. 16: 293–322
Lutticken C, Wegenka UM, Yuan J, Buschmann Y, Schindler C, Ziemiecki A, Harpur AG, Wilks AF, Yasukawa K, Taga T, Kishimoto T, Barbieri G, Pellegrini S, Sendtner M, Heinrich PC, Horn F . 1994 Science 263: 89–92
Matsuda T, Fukada T, Takahashi-Tezuka M, Okuyama Y, Fujitani Y, Hanazono Y, Hirai H, Hirano T . 1995a J. Biol. Chem. 270: 11037–11039
Matsuda T, Takahashi-Tezuka M, Fukada T, Okuyama Y, Fujitani Y, Tsukada S, Mano H, Hirai H, Witte ON, Hirano T . 1995b Blood 85: 627–633
Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, Lapidot Z, Leeder JS, Freedman M, Cohen A, Gazit A, Levitzki A, Roifman CM . 1996 Nature 379: 645–648
Narazaki M, Witthuhn BA, Yoshida K, Silvennoinen O, Yasukawa K, Ihle JN, Kishimoto T, Taga T . 1994 Proc. Natl. Acad. Sci. USA 91: 2285–2289
Nosaka T, Kitamura T . 2000 Int. J. Hematol. 71: 309–319
Ogata A, Chauhan D, Teoh SP, Urashima M, Schlossman RL, Anderson KC . 1997 J. Immunol. 159: 2212–2221
Parganas E, Wang D, Stravopodis D, Topham DJ, Marine J-C, Teglund S, Vanin EF, Bodner S, Colamonici OR, van Deursen JM, Grosveld G, Ihle JN . 1998 Cell 93: 385–393
Pear WS, Nolan GP, Scott ML, Baltimore D . 1993 Proc. Natl. Acad. Sci. USA 90: 8392–8396
Rane SG, Reddy EP . 2000 Oncogene 19: 5662–5679
Schuringa JJ, Jonk LJ, Dokter WH, Vellenga E, Kruijer W . 2000 Biochem. J. 347: 89–96
Sengupta TK, Talbot ES, Scherle PA, Ivashkiv LB . 1998 Proc. Natl. Acad. Sci. USA 95: 11107–11112
Stahl N, Boulton TG, Farruggella T, Ip NY, Davis S, Witthuhn B, Quelle FW, Silvennoinen O, Barbieri G, Pellegrini S, Ihle JN, Yancopoulos GD . 1994 Science 263: 92–95
Treon SP, Anderson KC . 1998 Curr. Opin. Hematol. 5: 42–48
Ui M, Okada T, Hazeki K, Hazeki O . 1995 Trends Biochem. Sci. 20: 303–307
Yang Y, Vanin EF, Whitt MA, Fornerod M, Zwart R, Schneiderman RD, Grosveld G, Nienhuis AW . 1995 Hum. Gene Ther. 6: 1203–1213
Zhang XK, Blenis J, Li HC, Schindler C, Chenkiang S . 1995 Science 267: 1990–1994
Acknowledgements
We thank JJ Krolewski (University of California, Irvine, CA, USA) for Tyk2 cDNA plasmids and L Samelson (NIH, Bethesda, MD, USA) for helpful discussion and comments.
Author information
Authors and Affiliations
Corresponding author
Additional information
This study is a ‘United States Government Work’ paper, as identified by the US Copyright Act
Rights and permissions
About this article
Cite this article
Kopantzev, Y., Heller, M., Swaminathan, N. et al. IL-6 mediated activation of STAT3 bypasses Janus kinases in terminally differentiated B lineage cells. Oncogene 21, 6791–6800 (2002). https://doi.org/10.1038/sj.onc.1205815
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205815
Keywords
This article is cited by
-
Egr-1 functions as a master switch regulator of remote ischemic preconditioning-induced cardioprotection
Basic Research in Cardiology (2020)
-
Effects of AG490 on lens epithelial cell death induced by H2O2
Japanese Journal of Ophthalmology (2010)
-
Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells
Oncogene (2003)